Printer Friendly

Ionix and Tripos Collaborate On Discovery of Novel Analgesics.

Business Editors & Health/Medical Writers


CAMBRIDGE, England--(BW HealthWire)--May 1, 2002

Ionix Pharmaceuticals, Ltd., the European analgesic drug discovery company announced today that it has signed an agreement with Tripos, Inc., a leading provider of high-value chemistry services, to collaborate on the design and synthesis of drug-like chemical compounds for evaluation as potential inhibitors of an Ionix drug target.

Ionix utilises ion channel drug targets that are involved in the perception and signalling of pain, with a focus on the discovery of drugs that act on molecular targets expressed in the peripheral nervous system. The collaboration is centred on an ion channel drug target. Target validation studies indicate that drugs which block this ion channel may lead to the development of potent new medicines for the treatment of chronic inflammatory and neuropathic pain.

In collaboration with medicinal chemists at Ionix, Tripos will utilise LeadQuest(R) chemical compound libraries, LeadFocus(TM) and LeadHopping(TM) chemistry services using its ChemSpace(TM) technology to select and synthesize compounds for the Ionix ion channel target. Ionix' medicinal chemists are providing a number of lead structures, enabling Tripos to design, select and produce novel compound libraries. Ionix scientists in Cambridge will conduct screening of compounds for target selectivity and functionality, and will undertake optimisation of promising drug leads.

Phil Birch, CSO of Ionix Pharmaceuticals, said:

"We are impressed by Tripos' expertise in the design of `druggable' lead structures, their library synthesis capabilities and their commitment to move programmes forward quickly. We are looking forward to working with Tripos to accelerate our discovery programmes."

Peter Hecht, Senior Vice President, Discovery Research Operations and Managing Director Tripos Receptor Research said: "Ionix is the leading biotechnology company in the field of analgesic drug discovery. We are delighted that they have chosen to collaborate with Tripos in this exciting area of research."

Ionix will own, develop and commercialise drug candidates that derive from the collaboration. Tripos will receive programme funding from Ionix, and downstream payments for successful development and commercialisation of product candidates.

Notes to Editors

About Ionix Pharmaceuticals

Ionix Pharmaceuticals (, based in Cambridge UK, is focused on the research and development of novel analgesic drugs. There is a massive unmet clinical need in the treatment of pain associated with chronic debilitating diseases such as osteoarthritis, diabetes, cancer and multiple sclerosis. Ionix uses proprietary ion channel drug targets that are involved in the perception and signalling of pain, with a focus on the discovery of drugs that act in the peripheral nervous system. This will allow the discovery of highly selective and efficacious medicines, without the side effects that are associated with today's CNS-acting drugs.

About Tripos, Inc.

Tripos ( is a leading provider of discovery chemistry, integrated discovery software products, software consulting services, and discovery research services to the pharmaceutical, biotechnology, agrochemical, and other life sciences industries. The company combines information technology and scientific research to optimize and accelerate molecular research for the discovery of new products by customers.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 1, 2002
Previous Article:White Electronic Designs Reports Second Quarter Fiscal 2002 Results.
Next Article:Loudcloud to Present At the JP Morgan H&Q 30th Annual Technology Conference.

Related Articles
Tripos and ONYX announce joint agreement for new high throughput screening software.
Spotfire and Tripos Partner to Deliver Fully-Integrated Data Management and Analysis Solution.
Signase Announces Second Round of Financing.
InforSense and Tripos Announce Alliance to Improve Drug Discovery Decision-Making.
InforSense and Tripos Announce Alliance to Improve Drug Discovery Decision-Making.
Tripos Announces New Software for Automatic Flexible Molecular Alignment.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters